140 related articles for article (PubMed ID: 9072430)
41. Renoprotective effect of enalapril in uninephrectomized spontaneously hypertensive rats with neonatal streptozotocin-induced diabetes.
Sato Y; Iwase M; Wakisaka M; Yoshizumi H; Nunoi K; Yoshinari M; Fujishima M
Diabetes Res Clin Pract; 1995 Sep; 29(3):153-61. PubMed ID: 8591707
[TBL] [Abstract][Full Text] [Related]
42. [Effects of CS-866, an angiotensin II receptor antagonist, in 5/6 nephrectomized spontaneously hypertensive rats].
Xu HL; Yoshida K; Wu XM; Kohzuki M
Nihon Jinzo Gakkai Shi; 2001 Oct; 43(7):580-8. PubMed ID: 11725555
[TBL] [Abstract][Full Text] [Related]
43. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors.
Kohzuki M; Kanazawa M; Liu PF; Kamimoto M; Yoshida K; Saito T; Yasujima M; Sato T; Abe K
J Hypertens; 1995 Dec; 13(12 Pt 2):1785-90. PubMed ID: 8903652
[TBL] [Abstract][Full Text] [Related]
44. Differential response of angiotensin peptides in the urine of hypertensive animals.
Yamada K; Iyer SN; Chappell MC; Brosnihan KB; Fukuhara M; Ferrario CM
Regul Pept; 1999 Mar; 80(1-2):57-66. PubMed ID: 10235635
[TBL] [Abstract][Full Text] [Related]
45. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
46. [Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
Krasnikova TL
Klin Med (Mosk); 1996; 74(3):17-21. PubMed ID: 8926692
[No Abstract] [Full Text] [Related]
47. Losartan versus captopril in elderly patients with heart failure.
Sechi LA; Catena C; Bartoli E
Lancet; 1997 May; 349(9063):1474; author reply 1475. PubMed ID: 9164337
[No Abstract] [Full Text] [Related]
48. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.
Gardiner SM; March JE; Kemp PA; Mullins JJ; Bennett T
Br J Pharmacol; 1995 Oct; 116(4):2237-44. PubMed ID: 8564254
[TBL] [Abstract][Full Text] [Related]
49. Effects of tight blood pressure control on glomerular hypertrophy in a model of genetic hypertension and experimental diabetes mellitus.
Amazonas RB; Lopes de Faria JB
Life Sci; 2006 Oct; 79(22):2135-43. PubMed ID: 16890245
[TBL] [Abstract][Full Text] [Related]
50. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
Zhou X; Matavelli LC; Ono H; Frohlich ED
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F871-9. PubMed ID: 15900021
[TBL] [Abstract][Full Text] [Related]
51. [What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Eguchi K; Kario K; Shimada K
Nihon Rinsho; 2002 Sep; 60 Suppl 9():679-84. PubMed ID: 12387069
[No Abstract] [Full Text] [Related]
52. Effect of antihypertensive treatment with alacepril on insulin resistance in diabetic spontaneously hypertensive rats.
Sato T; Nara Y; Kato Y; Yamori Y
Metabolism; 1996 Apr; 45(4):457-62. PubMed ID: 8609831
[TBL] [Abstract][Full Text] [Related]
53. [Medical angiotensin II-receptor blockade in hypertension and heart failure].
van Zwieten PA; Lie KI
Ned Tijdschr Geneeskd; 1995 Jul; 139(30):1529-33. PubMed ID: 7675129
[No Abstract] [Full Text] [Related]
54. Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats.
Chauvin B; Richer C; Giudicelli JF
Br J Pharmacol; 1995 Oct; 116(4):2229-36. PubMed ID: 8564253
[TBL] [Abstract][Full Text] [Related]
55. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
[TBL] [Abstract][Full Text] [Related]
56. Losartan versus captopril in elderly patients with heart failure.
Fournier A; Achard JM; Fernandez LA
Lancet; 1997 May; 349(9063):1473-4; author reply 1475. PubMed ID: 9164336
[No Abstract] [Full Text] [Related]
57. Effects of the angiotensin II receptor antagonist losartan on 24-hour blood pressure profiles of primary and secondary hypertensive rats.
Schnecko A; Witte K; Lemmer B
J Cardiovasc Pharmacol; 1995 Aug; 26(2):214-21. PubMed ID: 7475045
[TBL] [Abstract][Full Text] [Related]
58. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
Pitt B; Segal R; Martinez FA; Meurers G; Cowley AJ; Thomas I; Deedwania PC; Ney DE; Snavely DB; Chang PI
Lancet; 1997 Mar; 349(9054):747-52. PubMed ID: 9074572
[TBL] [Abstract][Full Text] [Related]
59. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
Ruff D; Gazdick LP; Berman R; Goldberg AI; Sweet CS
J Hypertens; 1996 Feb; 14(2):263-70. PubMed ID: 8728306
[TBL] [Abstract][Full Text] [Related]
60. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report.
Weber MA
Am J Hypertens; 1992 Dec; 5(12 Pt 2):247S-251S. PubMed ID: 1290620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
